269 related articles for article (PubMed ID: 29551430)
21. Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists.
Gnoth CH; Gödtke K; Freundl G; Godehardt E; Kienle E
Gynecol Obstet Invest; 1999; 47(1):37-41. PubMed ID: 9852390
[TBL] [Abstract][Full Text] [Related]
22. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
Mitwally MF; Gotlieb L; Casper RF
Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
[TBL] [Abstract][Full Text] [Related]
24. Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
[TBL] [Abstract][Full Text] [Related]
25. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
26. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
[TBL] [Abstract][Full Text] [Related]
27. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study.
Marik JJ
Obstet Gynecol; 1998 May; 91(5 Pt 1):793-4. PubMed ID: 9572232
[No Abstract] [Full Text] [Related]
28. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
29. Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal "add-back" paradigms.
Adashi EY
Keio J Med; 1995 Dec; 44(4):124-32. PubMed ID: 8587224
[TBL] [Abstract][Full Text] [Related]
30. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.
Sagsveen M; Farmer JE; Prentice A; Breeze A
Cochrane Database Syst Rev; 2003; 2003(4):CD001297. PubMed ID: 14583930
[TBL] [Abstract][Full Text] [Related]
31. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
Pierce SJ; Gazvani MR; Farquharson RG
Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
[TBL] [Abstract][Full Text] [Related]
32. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms.
Adashi EY
Hum Reprod; 1994 Jul; 9(7):1380-97. PubMed ID: 7962453
[TBL] [Abstract][Full Text] [Related]
33. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
34. [The role of the combined balneotherapeutic treatment as the 'add-back therapy' against the background of the anti-hormonal effects of the agonists of gonadotropin-releasing hormone in the women suffering from endometriosis genitalis externa].
Akhkubekova NK; Kaysinova AS; Fedorov AA; Efimenko NB; Gaidamaka II; Chalaja EN; Cherevashchenko LA; Tsallagova LV; Urvacheva EE; Ovsienko AB
Vopr Kurortol Fizioter Lech Fiz Kult; 2018; 95(5):31-39. PubMed ID: 30412147
[TBL] [Abstract][Full Text] [Related]
35. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
Gram IT; Ursin G; Spicer DV; Pike MC
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1117-20. PubMed ID: 11700258
[TBL] [Abstract][Full Text] [Related]
36. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms.
Kaser DJ; Missmer SA; Berry KF; Laufer MR
J Pediatr Adolesc Gynecol; 2012 Apr; 25(2):105-108. PubMed ID: 22154396
[TBL] [Abstract][Full Text] [Related]
37. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
[TBL] [Abstract][Full Text] [Related]
38. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
Niu ZR; Yue XJ; Kong QY; Wang YF; Yao YQ
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
[TBL] [Abstract][Full Text] [Related]
39. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
[TBL] [Abstract][Full Text] [Related]
40. A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women.
Li Z; Zhang HY; Zhu YJ; Hu YJ; Qu PP
Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():164-8. PubMed ID: 25461372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
